|
629
|
| 3341 |
NOS3
|
|
interacts (colocalizes) with
|
HSP90B1
|
|
|
17855507
|
Amyotrophic lateral sclerosis
|
|
1,176
|
| 7791 |
ob/ob mouse
|
NOT |
affects_expression of
|
NOS3
|
|
|
15805118
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,188
|
| 7892 |
obesity, high-fat diet-induced
|
NOT |
affects_expression of
|
NOS3
|
in skeletal muscle
|
|
11590438
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,375
|
| 9419 |
PTGER2
|
|
affects_expression of
|
NOS3
|
in lumbar spinal cord; in SOD1G93A mutant mice
|
|
18825663
|
Amyotrophic lateral sclerosis
|
|
2,036
|
| 16194 |
REN
|
|
decreases_activity of
|
NOS3
|
in aorta; after insulin stimulation, in Ren-2 rats
|
| 16196 |
Valsartan
|
|
increases_activity of
|
NOS3
|
in aorta; in Ren-2 rats, after insulin stimulation
|
| 16198 |
Tempol
|
|
increases_activity of
|
NOS3
|
in aorta; in Ren-2 rats, after insulin stimulation
|
|
17533199
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,118
|
| 17310 |
Nebivolol
|
|
increases_activity of
|
NOS3
|
|
| 17311 |
Atenolol
|
NOT |
increases_activity of
|
NOS3
|
|
|
18772860
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,119
|
| 17386 |
Angiotensin II
|
|
decreases_activity of
|
NOS3
|
via uncoupling of the active homodimer
|
| 17387 |
Nebivolol
|
NOT |
decreases_activity of
|
NOS3
|
after angiotensin II treatment
|
|
16940222
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,122
|
| 17393 |
HDL
|
|
increases_activity of
|
NOS3
|
in aorta; via dimerization of NOS3
|
|
19273745
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,124
|
| 17412 |
NOS3
|
|
affects_activity of
|
relaxation of vascular smooth muscle
|
if induced by nebivolol
|
|
16116070
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,125
|
| 17442 |
Nebivolol
|
|
increases_activity of
|
NOS3
|
in obese Zucker rats
|
|
20176997
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,130
|
| 17530 |
L-NAME
|
|
decreases_activity of
|
NOS3
|
|
| 17531 |
NOS3
|
|
affects_quantity of
|
NO
|
|
| 17532 |
NOS3
|
|
decreases_quantity of
|
BACE1
|
|
| 17533 |
NOS3
|
|
decreases_quantity of
|
Amyloid beta peptide
|
|
|
21127294
|
Alzheimer disease
|
|
2,131
|
| 17568 |
Streptozocin-induced diabetes
|
|
decreases_phosphorylation of
|
NOS3
|
at Ser1177
|
| 17572 |
Telmisartan
|
|
decreases_phosphorylation of
|
NOS3
|
at Ser1177, in streptozotocin-diabetic rats
|
| 17573 |
Telmisartan
|
NOT |
decreases_activity of
|
NOS3
|
in streptozotocin-diabetic rats
|
|
18539157
|
Diabetes mellitus, type II
Diabetes mellitus, type I
Insulin resistance
|
|
2,135
|
| 17578 |
NOS3
|
|
affects_quantity of
|
NOS3 homodimer
|
if NOS3 is overexpressed
|
| 17580 |
GCH1
|
NOT |
affects_expression of
|
NOS3
|
if GCH1 is overexpressed
|
| 17581 |
NOS3
|
|
affects_quantity of
|
Tetrahydrobiopterin
|
if NOS3 is overexpressed
|
| 17604 |
NOS3
|
|
increases_quantity of
|
NO
|
if NOS3 is overexpressed
|
| 17606 |
Tetrahydrobiopterin
|
|
affects_activity of
|
NOS3
|
|
|
16179591
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,138
|
| 17648 |
NOS3
|
|
affects_activity of
|
vasodilation
|
if induced by HDL
|
| 17650 |
AKT1
|
|
increases_phosphorylation of
|
NOS3
|
at Ser1177, if induced by HDL
|
| 17667 |
Sphingosylphosphorylcholine
|
|
increases_activity of
|
NOS3
|
|
| 17668 |
Sphingosine 1-phosphate
|
|
increases_activity of
|
NOS3
|
|
| 17669 |
Lysosulfatide
|
|
increases_activity of
|
NOS3
|
|
| 17683 |
AKT1
|
|
increases_activity of
|
NOS3
|
via phosphorylation at Ser1177
|
|
14966566
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,139
|
| 17701 |
AKT1
|
|
increases_activity of
|
NOS3
|
|
| 17714 |
AKT1
|
|
increases_phosphorylation of
|
NOS3
|
at Ser1177
|
| 17715 |
Ca2+
|
|
increases_activity of
|
NOS3
|
|
|
10376603
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,141
|
| 17766 |
Sphingosine 1-phosphate
|
|
increases_activity of
|
NOS3
|
|
| 17770 |
CAMKK2
|
|
affects_activity of
|
NOS3
|
if induced by S1P or HDL
|
| 17772 |
HDL
|
|
increases_activity of
|
NOS3
|
|
| 17777 |
STK11
|
|
affects_activity of
|
NOS3
|
if SR-BI-mediated
|
| 17816 |
AMPK
|
|
increases_activity of
|
NOS3
|
|
| 17817 |
NOS3
|
|
decreases_expression of
|
VCAM1
|
|
| 17818 |
NOS3
|
|
decreases_activity of
|
monocyte adhesion
|
|
| 17829 |
phosphatidylinositol 3-kinase signaling
|
|
increases_activity of
|
NOS3
|
|
|
20018878
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,558
|
| 33124 |
NOS3
|
|
affects_activity of
|
atherosclerotic lesions
|
|
| 33125 |
NOS3
|
|
affects_activity of
|
Alzheimer disease
|
|
|
16973241
|
Alzheimer disease
Metabolic
Atherosclerosis
|
|
3,752
|
| 36504 |
Diabetes mellitus, type II
|
|
decreases_expression of
|
NOS3
|
in kidney
|
| 36505 |
Pioglitazone
|
|
increases_expression of
|
NOS3
|
in kidney; in diabetic mice
|
|
16609149
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,181
|
| 43013 |
Schizophrenia
|
|
decreases_activity of
|
NOS3
|
in postmortem brain
|
|
12363386
|
Schizophrenia
|
|
4,534
|
| 45446 |
NOS3
|
|
affects_activity of
|
abnormal mitochondrial physiology
|
|
| 45512 |
NOS3
|
|
affects_activity of
|
Mitochondrial respiratory chain complex I
|
|
|
22138560
|
Diabetes mellitus, type II
Developmental
Insulin resistance
Glaucoma, primary open angle
|
|
4,699
|
| 46636 |
NOS3
|
|
decreases_quantity of
|
Arginine
|
|
| 46642 |
NOS3
|
|
increases_quantity of
|
NO
|
|
| 46645 |
NOS3
|
|
increases_quantity of
|
Citrulline
|
|
|
7510950
|
Metabolic
Cardiovascular disease
|
|
4,710
|
| 46689 |
NOS3
|
|
increases_quantity of
|
NO
|
in vascular endothelial cells
|
|
7536096
|
Cardiovascular disease
|
|
4,713
|
| 46707 |
NOS3
|
|
decreases_quantity of
|
Homoarginine
|
to produce NO
|
|
24004504
|
Stroke, ischemic
Cardiovascular disease
|
|
4,714
|
| 46717 |
NOS3
|
|
is_expressed_in
|
aortic endothelial cell
|
and is responsible for steady state NO production
|
|
23980179
|
Cardiovascular disease
|
|
4,717
|
| 46746 |
CRP
|
|
decreases_expression of
|
NOS3
|
by increasing the expression of RAGE
|
| 46747 |
CRP
|
|
decreases_quantity of
|
NOS3
|
by increasing the expression of RAGE
|
| 46755 |
AGER
|
|
decreases_expression of
|
NOS3
|
by increasing the ROS level
|
| 46756 |
AGER
|
|
decreases_quantity of
|
NOS3
|
by increasing the ROS level
|
|
22301267
|
Cardiovascular disease
|
|
4,724
|
| 46791 |
NOS3
|
|
is localized in
|
caveola
|
|
| 46798 |
SCARB1
|
|
increases_activity of
|
NOS3
|
by regulating the HDL-cholesterol transport into caveolae
|
| 46803 |
HDL
|
|
increases_activity of
|
NOS3
|
by increasing the cholesterol content in caveolae
|
|
12922018
|
Cardiovascular disease
Atherosclerosis
|
|
4,725
|
| 46792 |
HDL
|
|
increases_activity of
|
NOS3
|
|
| 46809 |
HDL
|
|
increases_activity of
|
NOS3
|
in caveola
|
| 46811 |
LDL
|
NOT |
affects_activity of
|
NOS3
|
in caveola
|
| 46821 |
SCARB1
|
|
increases_activity of
|
NOS3
|
|
| 46836 |
protein kinase B signaling
|
|
increases_activity of
|
NOS3
|
after activation of SCARB1 with HDL
|
| 46837 |
MAPK cascade
|
|
increases_activity of
|
NOS3
|
after activation of SCARB1 with HDL
|
| 46846 |
SCARB1
|
|
increases_phosphorylation of
|
NOS3
|
via PI3K-Akt signaling
|
|
12922018
|
Cardiovascular disease
Atherosclerosis
|
|
4,736
|
| 47038 |
EDN1
|
|
increases_quantity of
|
NOS3
|
via activation of ETB receptors and PI3K
|
| 50712 |
EDN1
|
|
increases_expression of
|
NOS3
|
via activation of ETB receptors and PI3K
|
|
15113749
|
Cardiovascular disease
|
|
4,737
|
| 46857 |
EDN1
|
|
increases_expression of
|
NOS3
|
via ETA receptors (EDNRA)
|
| 47040 |
EDNRA
|
|
increases_expression of
|
NOS3
|
if ETA has been induced by endothelin-1
|
|
10519149
|
Cardiovascular disease
|
|
4,739
|
| 46859 |
VEGFA
|
|
increases_expression of
|
NOS3
|
|
| 46871 |
sFLT1
|
|
decreases_activity of
|
NOS3
|
via antagonizing VEGFA activity
|
| 46872 |
sFLT1
|
|
decreases_phosphorylation of
|
NOS3
|
|
|
21139021
|
Preeclampsia/eclampsia 1
Cardiovascular disease
|
CIDeRplus